



UNITAID Executive Board

20th Session

12 - 13 June 2014

WHO Headquarters, Salle C

Geneva, Switzerland

Resolution n° 2

No-cost Extension

Narrowing the gap: Expanding and Accelerating Access to Diagnostics for patients at risk of Multi-Drug Resistant Tuberculosis (MDR-TB) (“the Expand-TB Project”)

The Board recalls EB-7 Resolution No.4 dated 2-3 April 2008 and EB-10 Resolution No.8 dated 12-13 May 2009, by which it approved total funding of US\$ 87,611,982 for the Expand-TB Project to 31 December 2013. The Board notes that during 2013, the UNITAID Secretariat has since approved a one year no-cost extension of the Project ending 31 December 2014. The Board now notes that the WHO Global TB Department has made a request for re-programming and a final no-cost extension of the Project to 31 December 2015.

The Board acknowledges the rationale of supporting this request in order to ensure the successful transition of the remaining countries with additional results. The Board understands that the transition process is dependent on the Global Fund’s new Funding Model which commenced in April 2013, thus requiring additional time for countries to transition as well as scale up the program in MDR-TB. The Board recognises the importance and need for accelerating additional diagnosis of MDR TB cases and to access treatment through the national programs and sustain the gains made under this project. Therefore, the Board authorises the Executive Director to commit to a final no-cost extension up to 31 December 2015.

Lead Organisation: Global TB Department, World Health Organisation

Conditions:

1. Review and revision to the satisfaction of the UNITAID Secretariat of the Project Plan, Budget, and Log-frame.
2. Signature of an amendment to the current project Agreement extending the Project term to 31 December 2015.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board